National Health (Pharmaceutical Benefits) Regulations (Amendment)

STATUTORY RULES

1969 No. 107

__________

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1968.*

WHEREAS it is provided by sub-section (4.) of section 101 of the National Health Act 1953-1968 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS sub-section (4.) of section 101 of the National Health Act 1953-1968 came into operation on the first day of March, 1960:

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1968, namely, each of the drugs and medicinal preparations specified in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations as amended by the following Regulations that were not pharmaceutical benefits under the National Health Act 1953-1958 immediately before the first day of March, 1960:

NOW THEREFORE I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1968.

Dated this twenty-fourth day of July, 1969.

Paul Hasluck

Governor-General.

By His Excellency’s Command,

(SGD.) A. J. FORBES

Minister of State for Health.

__________

Amendments of the National Health (Pharmaceutical Benefits) Regulations†

Commencement.

1. These Regulations shall come into operation on the first day of August, 1969.

Standards of composition and purity of pharmaceutical benefits and additives.

2. Regulation 35 of the National Health (Pharmaceutical Benefits) Regulations is amended by adding at the end thereof the following sub-regulations:—

“ (9.) Where the letters ‘ B.P. 1963 ’ appear after the name of the pharmaceutical benefit or the additive, the standards of composition and purity are those constituted by the description of that pharmaceutical benefit and of its ingredients, or of that additive, as the case may be, in the edition of the book called the British Pharmacopoeia published under the direction of the General Medical Council of the United Kingdom in the year 1963, as affected by the additions or amendments contained in the 1964 Addendum to that book, in the 1966 Addendum to that book and in the amendments of that book and those Addenda published in 1967 under the direction of the General Medical Council of the United Kingdom.

* Notified in the Commonwealth Gazette on 1969.

† Statutory Rules 1960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote to Statutory Rules 1969, No. 44; and see also Statutory Rules 1969, No. 44.

18210/69—Price 40c 15/11.7.1969

“ (10.) Where the letters ‘ B.P.C. 1963 ’ appear after the name of the pharmaceutical benefit or the additive, the standards of composition and purity are those constituted by the description of that pharmaceutical benefit and of its ingredients, or of that additive, as the case may be, in the edition of the book called the British Pharmaceutical Codex published by direction of the Council of the Pharmaceutical Society of Great Britain in the year 1963 as amended by the 1966 supplement to that book.”.

First, Second, Third, Fourth and Fifth Schedules.

3. The First, Second, Third, Fourth and Fifth Schedules to the National Health (Pharmaceutical Benefits) Regulations are repealed and the following Schedules inserted in their stead:—

First Schedule

Regulation 10.

Drugs and Medicinal Preparations in the British Pharmacopoeia that are not to be supplied as or, except as specially provided, used in Pharmaceutical benefits

1. Acetomenaphthone	50. Chlorambucil
2. Acetomenaphthone Tablets	51. Chlordiazepoxide Capsules
3. Acetrizoic Acid	52. Chlordiazepoxide Hydrochloride
4. Alcohol Dehydrated	53. Chloroquine Phosphate
5. Almond Oil	54. Chloroquine Phosphate Injection
6. Aluminium Hydroxide Tablets	55. Chloroquine Sulphate
7. Amitriptyline Injection	56. Chlorothiazide
8. Amodiaquine Hydrochloride	57. Chlorotrianisene
9. Amphetamine Sulphate	58. Chlorotrianisene Capsules
10. Amphetamine Sulphate Tablets	59. Chlorphenesin
11. Amylobarbitone Sodium Tablets	60. Chlorproguanil Hydrochloride
12. Antazoline Hydrochloride	61. Chlorproguanil Tablets
13. Antimony Sodium Tartrate	62. Chlorpropamide
14. Antimony Sodium Tartrate Injection	63. Chlorthalidone
15. Apomorphine Hydrochloride	64. Cholera Vaccine
16. Apomorphine Injection	65. Choline Theophyllinate Tablets
17. Aspirin Phenacetin and Codeine Tablets	66. Cinchocaine Hydrochloride
18. Aspirin Phenacetin and Codeine Tablets Soluble	67. Cinnamon
19. Bacillus Calmette-Guérin Vaccine	68. Citric Acid, Anhydrous
20. Barium Sulphate	69. Cochineal
21. Belladonna Herb	70. Colchicine
22. Belladonna Herb, Powdered	71. Colchicum Corm
23. Bemegride	72. Colchicum Liquid Extract
24. Benzhexol Hydrochloride	73. Colistin Tablets
25. Benztropine Mesylate	74. Coriander
26. Betamethasone Sodium Phosphate Tablets	75. Coriander Oil
27. Bisacodyl	76. Corticotrophin
28. Bisacodyl Suppositories	77. Cresol and Soap Solution
29. Bisacodyl Tablets	78. Cresol
30. Botulinum Antitoxin	79. Crotamiton
31. Busulphan	80. Cyanocobalamin
32. Butobarbitone	81. Cyanocobalamin (87Co)
33. Butylated Hydroxyanisole	82. Cyanocobalamin (88Co)
34. Butylated Hydroxytoluene	83. Cyclamic Acid
35. Caffeine Hydrate	84. Cyclizine Tablets
36. Calciferol Solution	85. Cyclobarbitone Calcium
37. Calcium Cyclamate	86. Cyclomethycaine Sulphate
38. Caramiphen Hydrochloride	87. Cyclopenthiazide
39. Caramiphen Tablets	88. Cyclopentolate Hydrochloride
40. Caraway	89. Cyclopropane
41. Carbimazole	90. Cycloserine
42. Carbon Dioxide	91. Dapsone
43. Carbromal Tablets	92. Dequalinium Acetate
44. Cardamom Fruit	93. Dequalinium Chloride
45. Cascara	94. Desipramine Hydrochloride
46. Cascara Dry Extract	95. Desipramine Tablets
47. Catgut, Sterilised, Surgical	96. Dexamphetamine Sulphate
48. Cellulose, Oxidised	97. Dexamphetamine Tablets
49. Cetylpyridinium Chloride	98. Dextran 110 Injection

First Schedule—continued

99. Dextromethorphan Hydrobromide	165. Human Blood, Whole
100. Dextromethorphan Tablets	166. Human Red Blood, Corpuscles, Concentrated
101. Dextropropoxyphene Capsules	167. Human Fibrin Foam
102. Dextropropoxyphene Hydrochloride	168. Human Fibrinogen
103. Dextropropoxyphene Napsylate	169. Human Normal Gamma Globulin Injection
104. Diamorphine Hydrochloride	170. Human Plasma, Dried
105. Diamorphine Injection	171. Human Plasma Protein Fraction
106. Dibromopropamidine Isethionate	172. Human Plasma Protein Fraction, Dried
107. Dichloralphenazone	173. Human Serum, Dried
108. Dichlorophen	174. Human Thrombin
109. Dichlorphenamide	175. Hydrochlorothiazide
110. Diethylcarbamazine Citrate	176. Hydrocortisone Ointment
111. Diethylcarbamazine Tablets	177. Hydrocortisone Hydrogen Succinate
112. Digitalis Leaf	178. Hydrocortisone Sodium Succinate
113. Digitalis Prepared	179. Hydroflumethiazide
114. Digitoxin	180. Hydrogen Peroxide Solution, Strong
115. Diloxanide Furoate	181. Hydroxocobalamin
116. Dimenhydrinate	182. Hydroxychloroquine Sulphate
117. Dimenhydrinate Injection	183. Hyoscine Injection
118. Dimenhydrinate Tablets	184. Hyoscine Eye Ointment
119. Dimercaprol	185. Hyoscyamus
120. Dimethisterone	186. Hyoscyamus Dry Extract
121. Dimethisterone Tablets	187. Indigo Carmine
122. Diodone Injection	188. Iodinated (101I) Human Serum Albumin Injection
123. Diphtheria and Pertussis Vaccine	189. Iodipamide Meglumine Injection
124. Diphtheria, Tetanus and Poliomyelitis Vaccine	190. Iodised Oil Fluid Injection
125.Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine	191. Iopanoic Acid
126. Dipipanone Hydrochloride	192. Iopanoic Acid Tablets
127. Dipipanone Injection	193. Iophendylate Injection
128. Dodecyl Gallate	194. Iothalmic Acid
129. Domiphen Bromide	195. Ipecacuanha, Prepared
130. Dusting Powder Absorbable	196. Isocarboxazid
131. Edrophonium Chloride	197. Isocarboxazid Tablets
132. Emetine and Bismuth Iodide	198. Isoniazid
133. Emetine Hydrochloride	199. Isopropyl Alcohol
134. Erythromycin	200. Laevulose Injection
135. Ethchlorvynol	201. Lemon Peel, Dried
136. Ethinyloestradiol	202. Levallorphan Injection
137. Ethionamide	203. Levorphanol Tartrate
138. Ethisterone	204. Lignocaine and Adrenaline Injection
139. Ethopropazine Hydrochloride	205. Liothyronine Sodium
140. Ethotoin	206. Liquorice
141. Ethyl Chloride	207. Lucanthone Hydrochloride
142. Ethyl Oleate	208. Lucanthone Tablets
143. Ethylenediamine Hydrate	209. Lynoestrenol
144. Eugenol	210. Magnesium Stearate
145. Ferric Citrate (59Fe) Injection	211. Male Fern
146. Ferrous Fumarate	212. Maleic Acid
147. Ferrous Succinate Tablets	213. Measles Vaccine (Inactivated)
148. Fludrocortisone Acetate	214. Measles Vaccine (Live Attenuated)
149. Fluocinolone Acetonide	215. Mecamylamine Hydrochloride
150. Fluoxymesterone	216. Meglumine Iothalamate Injection
151. Gallamine Triethiodide	217. Melarsoprol
152. Gallamine Injection	218. Melarsoprol Injection
153. Gamma Benzene Hexachloride	219. Mepacrine Hydrochloride
154. Gelatin Sponge, Absorbable	220. Mephentermine Sulphate
155. Gentian	221. Meprobamate
156. Ginger	222. Meprobamate Tablets
157. Gold (198Au) Injection	223. Mercaptopurine
158. Griseofulvin	224. Mersalyl Acid
159. Halothane	225. Mestranol
160. Helium	226. Metaraminol Tartrate
161. Heparin	227. Methadone Hydrochloride
162. Hexylresorcinol	228. Methandienone
163. Histamine Acid Phosphate	229. Methicillin Sodium
164. Histamine Acid Phosphate Injection

First Schedule—continued

230. Methohexitone Injection	297. Phenelzine Sulphate 298. Phenelzine Tablets
231. Methoin	299. Phenindamine Tartrate
232. Methoserpidine	300. Phenindione
233. Methoserpidine Tablets	301. Phenmetrazine Hydrochloride
234. Methoxyflurane	302. Phenmetrazine Tablets
235. Methyl Hydroxybenzoate	303. Phenolphthalein Tablets
236. Methylamphetamine Hydrochloride	304. Phenolsulphonphthalein
237. Methylamphetarmine Injection	305. Phenoxybenzamine Hydrochloride
238. Methylamphetarmine Tablets 239. Methyldopa	306. Phenoxymethylpenicillin
240. Methylergometrine Maleate	307. Phentolamine Mesylate
241. Methylthiouracil	308. Phentolamine Injection
242. Methylthiouracil Tablets	309. Phytomenadione
243. Methyprylone	310. Phytomenadione Capsules
244. Methyprylone Tablets	311. Phytomenadione Tablets
245. Metronidazole	312. Piperazine Citrate
246. Nalorphine Hydrobromide	313. Piperazine Phosphate Tablets
247. Nandrolone Decanoate	314. Poldine Methylsulphate
248. Nandrolone Phenylpropionate	315. Poldine Tablets
249. Naphazoline Hydrochloride	316. Poliomyelitis Vaccine (In activated)
250. Nealbarbitone	317. Poliomyelitis Vaccine (Oral)
251. Nealbarbitone Tablets	318. Potassium Chloride Injection
252. Neostigmine Bromide	319. Prednisolone Sodium Phosphate Injection
253. Nialamide	320. Prednisolone Pivalate Injection
254. Nialamide Tablets	321. Prednisone
255. Niclosamide	322. Prednisone Acetate
256. Nicotinic Acid	323. Primaquine Phosphate
257. Nicoumalone	324. Probenecid
258. Nikethamide	325. Procainamide Tablets
259. Nikethamide Injection	326. Procaine and Adrenaline Injection
260. Nitrous Oxide	327. Prochlorperazine Maleate
261. Norethandrolone	328. Prochlorperazine Mesylate
262. Norethandrolone Tablets	329. Prochlorperazine Tablets
263. Norethisterone	330. Procyclidine Hydrochloride
264. Norethisterone Acetate	331. Progesterone
265. Norethisterone Tablets	332. Proguanil Hydrochloride
266. Norethynodrel	333. Promazine Hydrochloride
267. Noscapine	334. Promazine Injection
268. Novobiocin Calcium	335. Promazine Tablets
269. Novobiocin Sodium	336. Promethazine Theoclate
270. Novobiocin Tablets	337. Promethazine Theoclate Tablets
271. Nux Vomica	338. Propranolol Hydrochloride
272. Octyl Gallate	339. Propyl Gallate
273. Oestradiol Benzoate	340. Propyliodone
274. Opium	341. Propyliodone Injection
275. Opium, Powdered	342. Propyliodone Oily Injection
276. Orange Peel, Dried Bitter	343. Propylthiouracil
277. Orphenadrine Hydrochloride	344. Pyrazinamide
278. Oxygen	345. Pyridostigmine Bromide
279. Oxyphenbutazone	346. Pyrimethamine
280. Oxyphenbutazone Tablets	347. Pyroxylin
281. Oxyphencyclamine Hydrochloride	348. Quillaia
282. Oxytetracycline Dihydrate 283. Oxytocin Tablets	349. Quinine Dihydrochloride Injection
284. Paramothadione	350. Rabies Antiserum
285. Paramomycin Capsules	351. Rabies Vaccine
286. Paramomycin Sulphate	352. Sesame Oil
287. Pempidine Tartrate	353. Soda Lime
288. Penicillamine Hyrochloride	354. Sodium Acetate
289. Pentamidine Isethionate	355. Sodium Acetrizoate Injection
290. Pentamidine Injection	356. Sodium Acid Citrate
291. Pentolinium Tartrate Tablets	357. Sodium Antimonylgluconate
292. Percutaneous Bacillus Calmette-Guérin Vaccine	358. Sodium Antimonylgluconate Injection
293. Perphenazine	359. Sodium Aurothiomalate
294. Perphenazine Tablets	360. Sodium Bicarbonate Compound Tablets
295. Pethidine Tablets	361. Sodium Bicarbonate Injection
296. Phenacetin	362. Sodium Calciumedetate
	363. Sodium Chromate (51Cr) Solution

First Schedule—continued

364. Sodium Citrate Tablets	405. Tetanus Vaccine (Simple Solution)
365. Sodium Cyclamate	406. Tetrachloroethylene
366. Sodium Diatrizoate	407. Tetrachloroethylene Capsules
367. Sodium Diatrizoate Injection	408. Thiomersal
368. Sodium Fluoride	409. Thiopentone Sodium
369. Sodium Fusidate Capsules	410. Thiopentone Injection
370. Sodium Iodide (101I) Injection	411. Thioridazine Hydrochloride
371. Sodium Iodide (131I) Solution	412. Thyroid
372. Sodium Iodohippurate (131I) Injection	413. Thyroxine Sodium
373. Sodium Iothalamate Injection	414. Tolazoline Hydrochloride
374. Sodium Lauryl Sulphate	415. Tolbutamide
375. Sodium Phosphate (32P) Injection	416. Tranylcypromine Sulphate
376. Sodium Stibogluconate	417. Tranylcypromine Tablets
377. Sodium Stibogluconate Injection	418. Triamcinolone Acetonide
378. Solapsone	419. Tramteiene Capsules
379. Solapsone Tablets	420. Trichloroethylene
380. Spironolactone	421. Tricyclamol Chloride
381. Staphylococcus Antitoxin	422. Tryparsamide
382. Stibophen	423. Tryparsamide Injection
383. Stibophen Injection	424. Tuberculin, Old
384. Stramonium	425. Tuberculin Purified Protein Derivative
385. Sulphadiazine Sodium	426. Tubocurarine Chloride
386. Sulphadimethoxine	427. Tubocurarine Injection
378. Sulphadimidie Sodium	428. Typhoid-Paratyphoid A and B
388. Sulphamethizole	429. Typhoid-Paratyphoid A and B and Cholera Vaccine
389. Sulphamethoxydiazine	430. Typhoid-Paratyphoid A and B and Tetanus Vaccine
390. Sulphamethoxypridazine	431. Typhoid-Paratyphoid A, B and C Vaccine
391. Sulphapyridine	432. Undecenoic Acid
392. Sulphinpyrazone	433. Urea
393. Sulphocromophthalein Sodium	434. Urea Injection
394. Sulphomyxin Sodium	435. Vancomycin Hydrochloride
395. Sulthiame	436. Vancomycin Injection
396. Suramin	437. Vinyl Ether
397. Suramin Injection	438. Vitamin A Ester Concentrate
398. Suxamethonium Chloride	439. Yellow Fever Vaccine
399. Testosterone	440. Zinc Undecenoate
400. Testosterone Phenylpropionate	441. Zinc Undecenoate Ointment
401. Testosterone Phenylpropionate Injection
402. Testosterone Propionate
403. Tetanus and Pertussis Vaccine
404. Tetanus Vaccine (Alum Precipitated)

_______________

Second Schedule

Regulation 10 (3.).

Allowable Compounds (if any) of Certain Drugs or Medicinal Preparations

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Allowable Compounds (if any)
1	Acetylcysteine......................	—
2	Acrylic Resin.......................	—
3	Amino Acids.......................	Amino Acids with Sorbitol
		Amino Acids with Sorbitol and Ethanol
4	Amphotericin B.....................	Tetracycline with a buffering agent and Amphotericin B.
5	Antazoline Sulphate ..................	Antazoline Sulphate with Naphazoline Nitrate B.P.
6	Ascorbic Acid, B.P. ..................	Vitamin A with Thiamine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D
7	Attapulgite........................	Dihydrostreptomycin Sulphate B.P. 1958 with Attapulgite, Pectin and Hydrated Alumina Powder B.P.
8	Bacitracin, B.P......................	Polymyxin B Sulphate B.P. with Bacitracin B.P. and Neomycin Sulphate B.P.
9	Bacitracin Zinc......................	Bacitracin Zinc with Neomycin Undecenoate
10	Betamethasone Acetate ................	Betamethasone Acetate with Betamethasone B.P.

Second Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Allowable Compounds (if any)
11	Betamethasone, BP ....................	Betamethasone B.P. with Betamethasone Acetate
12	Betamethasone Sodium Phosphate, BP	—
13	Betamethasone Phosphate ................	—
14	Brompheniramine Maleate ...............	—
15	Buclosamide.........................	Buclosamide with Salicylic Acid
		Buclosamide with Salicylic Acid and Hydrocortisone Acetate B.P.
16	Calciferol, BP........................	—
17	Carbachol, BP........................	—
18	Carbinoxamine Maleate.................	—
19	Carbromal, BP.......................	Carbromal B.P. with Pentobarbitone Sodium B.P.
20	Cetrimide...........................	Cetrimide with Terric N.8 and Spearmint Oil
21	Chloramine, BPC......................	—
22	Chloramphenicol, BP...................	Chloramphenicol B.P. with Polymyxin B Sulphate B.P.
		Chloramphenicol B.P. with Hydrocortisone Acetate B.P.
23	Chlorhexldine Gluconate.................	—
24	Chlorpheniramine Maleate, BP.............	—
25	Chlorpromazine Hydrochloride, BP..........	—
26	Chlortetracycline Hydrochloride, BP.........	—
27	Clemizole Tannate ....................	—
28	Cortisone Acetate, BP ..................	—
29	Cymogran ..........................	—
30	Cyproheptadine Hydrochloride, BP..........	—
31	Cyclizine Hydrochloride, BP..............	Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.
32	Danthron...........................	Danthron with Dioctyl Sodium Sulphosuccinate
33	Demecarium Bromide...................	—
34	DemethylchlortetracyclineHydrochloride, BP...	Demethylchlortetracycline Hydrochloride B.P. with Nystatin B.P.
35	Dexamethasone ......................	Dexamethasone with Framycetin Sulphate and Gramicidin
36	Dexamethasone Metasulphobenzoate.........	Dexamethasone Metasulphobonzoate with Framycetin Sulphate and Gramicidin
37	Dexchlorphcniramine Maleate.............	—
38	Dextran ...........................	Dextran with Dextrose B.P.
		Dextran in Normal Saline
39	Dicyclomine Hydrochloride, BP............	—
40	Dienoestrol, BP.......................	—
41	Digoxin, BP.........................	—
42	Dihydrostreptomycin Sulphate, BP 1958	Dihydrostreptomycin Sulphate B.P. 1958 with Attapulgite, Pectin and Hydrated Alumina Powder B.P.
		Dihydrostreptomycin Sulphate B.P. 1958 with Kaolin, Pectin and Aluminium Hydroxide Gel
43	Dihydrotachysterol, BP..................	—
44	Dimethicone, BPC.....................	—
45	Dioctyl Sodium Sulphosuccinate...........	Dioctyl Sodium Sulphosuccinate with Danthron
46	Diphenhydramine Hydrochloride, BP........	Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.
47	Diphenylpyraline Hydrochloride............	—
48	Diphtheria Vaccine, BP .................	Diphtheria Tetanus Vaccine B.P. Purified Toxoid (Aluminium Phosphate Adsorbed) B.P.
		Diphtheria Tetanus Purified Toxoid (Aluminium Phosphate Adsorbed) and Pertussis Vaccine B.P.
49	Ecothiopate Iodide ....................	—
50	Entsufon...........................	Hexachlorophane B.P. with Entsufon
51	Ergometrine Maleate...................	Oxytocin with Ergometrine Maleate

Second Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Allowable Compounds (if any)
52	Ergotamine Tartrate, BP .................	Ergotamine Tartrate B.P. with Caffeine B.P.
		Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.
		Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.
		Ergotamine Tartrate B.P. with Caffeine B.P. and Meclozine Hydrochloride B.P.
53	Erythromycin Oral Suspensions and Syrups....	—
54	Erythromycin Paediatric Drops.............	—
55	Ethosuximide .......................	—
56	Ferric Hydroxide......................	—
57	Ferrous Aminoacetosulphate..............	—
58	Ferrous Succinate, BP...................	—
59	Framycetin Sulphate....................	—
60	Fusidic Acid (Diethanolamine Salt)..........	—
61	Galactomin, Formula No 17...............	—
62	Galactomin, Formula No 19...............	—
63	Glucose Indicator.....................	—
64	Glyceryl Guaiacolate...................	Theophylline with Glyceryl Guaiacolate
65	Gramicidin..........................	Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin
		Gramicidin with Neomycin Sulphate B.P., Thonzonium Bromide, Thonzylamine Hydrochloride and Hydrocortisone Acetate B.P.
66	Hexachlorophane, BP...................	Hexachlorophane B.P. with Entsufon
		Hexachlorophane B.P. with Terric N.8
		Hexachlorophane B.P. in Soap Solution
		Hexachlorophane B.P. with Chloroxylenol
67	Hydrocortisone, BP....................	Hydrocortisone B.P. with Polymyxin B. Sulphate B.P. and Neomycin Sulphato B.P.
68	Hydrocortisone Acetate, BP...............	Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.
		Hydrocortisone Acetate B.P. with Gramicidin, Neomycin Sulphate B.P., Thonzonium Bromide and Thonzylamine Hydrochloride
		Hydrocortisone Acetate B.P. with Chloramphenicol B.P.
		Hydrocortisone Acetate B.P. with Oxytetracycline Hydrochloride B.P.
69	Idoxuridine..........................	—
70	Ipecacuanha, BP......................	Phenolphthalcin B.P. with Aloin B.P.C., Dry Extract of Belladonna B.P., Strychnine B.P.C. 1959 and Ipecacuanha B.P.
71	Isoprenaline Hydrochloride...............	—
72	Kanamycin Sulphate, BPC...............	—
73	Levallorphan Tartrate, BP................	Levallorphan Tartrate B.P. with Pethidine Hydrochloride B.P.
74	Lofenalac...........................	—
75	Magnesium Chloride BP.................	Ammonium Chloride B.P. with Sodium Chloride B.P., Potassium Chloride B.P. and Magnesium Chloride B.P.
		Sodium Lactate with Potassium Chloride B.P., Magnesium Chloride B.P. and Sodium Chloride B.P.
76	Mebhydrolin Napadisylate, BPC............	—
77	Meclozine Hydrochloride, BP.............	Ergotamine Tartrate B.P. with Caffeine B.P. and Meclozine Hydrochloride B.P.
78	Mepyramine Maleate, BP................	—
79	Methacycline........................	—
80	Methdilazine Hydrochloride..............	—
81	Methenamine Mandelate.................	—
82	Meglumine, BP.......................	Theophylline B.P. with Meglumine B.P.
83	Minafen............................	—

Second Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Allowable Compounds (if any)
84	Morphine Tartrate.....................	Morphine Tartrate with Tacrine
85	Naphazoline Nitrate, BP.................	Naphazoline Nitrate B.P. with Antazoline Sulphate
86	Neomycin Sulphate, BP.................	Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.
		Polymyxin B. Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.
		Neomycin Sulphate B.P. with Kaolin B.P.
		Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin
		Polymyxin B. Sulphate B.P. with Hydrocortisone B.P. and Neomycin Sulphate B.P.
		Neomycin Sulphate B.P. with Prednisolone Sodium Phosphate B.P.
87	Neomycin Undecenoate.................	Neomycin Undecenoate with Bacitracin Zinc
88	Neostigmine Methylsulphate, BP...........	—
89	Nicotinamide, BP.....................	Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D
90	Nitrofurantoin, BP.....................	—
91	Nortriptyline Hydrochloride, BP............	—
92	Nystatin, BP.........................	Tetracycline with a buffering agent and Nystatin B.P.
		Oxytetracycline Hydrochloride B.P. with a buffering agent and Nystatin B.P.
		Demethylchlortetracycline Hydrochloride B.P. with Nystatin B.P.
93	Nutramigen.........................	—
94	Oxytetracycline Hydrochloride, BP..........	Oxytetracycline Hydrochloride B.P. with Polymyxin B. Sulphate B.P.
		Oxytetracycline Hydrochloride B.P. with a buffering agent and Nystatin B.P.
		Oxytetracycline Hydrochloride B.P. with Hydrocortisone Acetate B.P.
95	Oxytocin...........................	Oxytocin with Ergometrine Maleate
96	Pancreatin Enzyme, USNF XII.............	—
97	Papaveretum, BPC.....................	Papaveretum B.P.C. with Hyoscine Hydrobromide B.P.
98	Penicillin, Benethamine, BPC.............	Penicillin, Benethamine B.P.C. with Procaine Penicillin B.P. and Sodium Penicillin B.P.
99	Penicillin, Benzathine, BP................	Penicillin, Benzathine B.P. with Procaine Penicillin B.P. and Potassium Penicillin B.P.
100	Penicillin, Benzyl, BP...................	Penicillin, Benzyl B.P. with Streptomycin Sulphate B.P.
		Fortified Procaine Penicillin Injection B.P.
		Penicillin, Benzyl B.P. with Procaine Penicillin B.P. and Streptomycin Sulphate B.P.
101	Penicillin, Phenoxymethyl (Benzathine, Calcium, Hydrabamine or Potassium Salt or Free Acid)	—
102	Penicillin, Potassium, BP................	Penicillin, Benzathine B.P. with Procaine Penicillin B.P. and Potassium Penicillin B.P.
103	Penicillin, Procaine, BP.................	Penicillin, Benzathine B.P. with Procaine Penicillin B.P. and Potassium Penicillin B.P.
		Fortified Procaine Penicillin Injection B.P.
		Penicillin, Benethamine B.P.C. with Procaine Penicillin B.P. and Sodium Penicillin B.P.
		Penicillin, Benzyl B.P. with Procaine Penicillin B.P. and Streptomycin Sulphate B.P.
104	Penicillin, Sodium, BP..................	Penicillin, Benethamine B.P. with Procaine Penicillin B.P. and Sodium Penicillin B.P.
105	Pertussis Vaccine, BP...................	Diphtheria, Tetanus Purified Toxoid (Aluminium Phosphate Adsorbed) and Pertussis Vaccine B.P.

Second Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Allowable Compounds (if any)
106	Pethidine Hydrochloride, B.P..............	Pethidine Hydrochloride B.P. with Levallorphan Tartrate B.P.
		Pethidine Hydrochloride B.P. with Scopolamine Hydrobromide B.P.
107	Phenethicillin Potassium, B.P..............	—
108	Pheniramine Maleate...................	—
109	Phenytoin B.P.C.......................	—
110	Pilocarpine Hydrochloride...............	—
111	Pipenzolate Methobromide...............	—
112	Pituitary (Posterior Lobe), Powdered, B.P.C....	—
113	Polymyxin B. Sulphate, B.P...............	Chloramphenicol B.P. with Polymyxin B. Sulphate B.P.
		Oxytetracycline Hydrochloride B.P. with Polymyxin B. Sulphate B.P.
		Polymyxin B. Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.
		Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin
		Polymyxin B. Sulphate B.P. with Propylene Glycol and Acetic Acid
		Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.
114	Polyvinyl Alcohol.....................	—
115	Methylprednisolone, B.P.................	—
116	Prednisolone Sodium Succinate............	—
117	Prednisolone Sodium Phosphate, B.P........	Neomycin Sulphate B.P. with Prednisolone Sodium Phosphate B.P.
118	Prednisolone Trimethylacetate, B.P..........	—
119	Primidone, B.P........................	—
120	Promethazine Hydrochloride, B.P...........	—
121	Riboflavine, B.P.......................	Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D
122	Senna Fruit, B.P. .....................	—
123	Silver Nitrate, Toughened, B.P.............	—
124	Sobee.............................	—
125	Sodium Aminosalicylate B.P..............	Sodium Aminosalicylate B.P. with Isoniazid B.P.
126	Sodium Lactate.......................	Sodium Lactate with Potassium Chloride B.P. and Sodium-Chloride B.P.
		Sodium Lactate with Potassium Chloride B.P., Magnesium Chloride and Sodium Chloride B.P.
		Sodium Lactate with Sodium Chloride B.P. and Dextrose B.P.
		Sodium Lactate with Sodium Chloride B.P.
		Sodium Lactate with Potassium Chloride B.P. and Dextrose B.P.
127	Sodium Potassium Tartrate, B.P.C...........	Compound Effervescent Powder B.P.C.
128	Sodium Tauroglycocholate, B.P.C. 1954	Sodium Tauroglycocholate B.P.C. 1954 with Cascara Dry Extract B.P.
129	Spearmint Oil, B.P.C....................	Terric N.8 with Spearmint Oil B.P.C. and Cetrimide B.P.
130	Strychnine, B.P.C. 1959.................	Phenolphthalein with Aloin, Dry Extract of Belladonna, Strychnine B.P.C. 1959 and Ipecacuanha
131	Sulphacetamide, B.P.C..................	Sulphacetamide B.P.C. with Sulphamerazine B.P. 1958 and Sulphadiazine B.P.
132	Sulphafurazole, B.P....................	—

Second Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Allowable Compounds (if any)
133	Sulphamerazine, B.P. 1958...............	Sulphamerazine B.P. 1958 with Sulphadiazine B.P. and Sulphathiazole B.P.C.
		Sulphamerazine B.P. 1958 with Sulphadiazine B.P. and Sulphacetamide B.P.C.
		Sulphamerazine B.P. 1958 with Sulphadiazine B.P. and Sulphadimidine B.P.
134	Sulphamethoxazole....................	—
135	Sulphaphenazole, B.P.C.................	—
136	Sulphathiazole, B.P.C...................	Sulphathiazole B.P.C. with Sulphamerazine B.P. 1958 and Sulphadiazine B.P.
137	Surgical Cement......................	—
138	Surgical Cement Solvent................	—
139	Tacrine............................	Morphine Sulphate B.P. with Tacrine
		Morphine Tartrate with Tacrine
140	Terric, N.8..........................	Hexachlorophane B.P. with Terric N.8.
		Terric N.8. with Spearmint Oil and Cetrimide B.P.
141	Tetanus Vaccine Purified Toxoid (Aluminium Phosphate Adsorbed), B.P.	Diphtheria and Tetanus Vaccine Purified Toxoid (Aluminium Phosphate Adsorbed) B.P.
		Diphtheria, Tetanus and Pertussis Vaccine Purified Toxoid (Aluminium Phosphate Adsorbed) B.P.
142	Tetracycline, B.P.C....................	Tetracycline B.P.C. with a buffering agent
		Tetracycline B.P.C. with a buffering agent and Amphotericin B.
		Tetracycline B.P.C. with a buffering agent and Nystatin B.P.
		Tetracycline B.P.C. with Nystatin B.P.
143	Thiamine Hydrochloride, B.P..............	Vitamin A with Thiamine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P., and Vitamin D
144	Thioridazine........................	—
145	Thonzonium Bromide..................	Thonzonium Bromide with Neomycin Sulphate B.P., Gramicidin, Thonzylamine Hydrochloride and Hydrocortisone Acetate B.P.
146	Thonzylamine Hydrochloride.............	Thonzylamine Hydrochloride, Thonzonium Bromide, Neomycin Sulphate B.P., Gramicidin, Thonzonium Bromide and Hydrocortisone Acetate B.P.
147	Tragacanth, Indian (Gum Karaya)..........	—
148	Trifluoperazine Hydrochloride, B.P..........	—
149	Triglyde...........................	—
150	Trimeprazine Tartrate, B.P.C..............	—
151	Triprolidine Hydrochloride, B.P............	—
152	Velactin...........................	—
153	Viprynium Embonate, B.P................	—
154	Vitamin A..........................	Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D
155	Vitamin D..........................	Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D

THIRD SCHEDULE

Regulation 11.

Drugs and Medicinal Preparations Additional to the Drugs and Medicinal Preparations in the British Pharmacopoeia

1. Acepifylline	6. Acetyl Sulphafurazole
2. Acetazolamide Sodium	7. Acidified Golden Syrup, A.P.F. 1955
3. Acetohexamide	8. Acriflavine, B.P.C. 1963
4. Acetylcholine Chloride	9. Acrylic Resin
5. Acetylcysteine	10. Adrenaline Hydrochloride

Third Schedule—continued

11. Adrenaline Mucate	75. Carbenicillin
	76. Carbenoxolone Sodium
	77. Carbinoxamine Maleate
12. Agar, B.P.C. 1954	78. Cardamon Aromatic Tincture, B.P.C.
13. Albumaid XP	79. Casein Hydrolysate
14. Aldosterone	80. Catechu Tincture, B.P.C.
15. Allpurinol	81. Cetomacrogol Emulsifying Wax, B.P.C.
16. Aloin, B.P.C.	82. Charcoal
17. Almond Oil Volatile Bitter, B.P.C. 1959	83. Chloramine, B.P.C.
18. Aloxiprin	84. Chloramphenicol Palmitate, B.P.C.
19. Aluminium Acetate Solution, B.P.C.	85. Chloramphenicol Stearate
20. Aluminium Hydroxide Mixture, A.P.F.	86. Chloramphenicol Succinate
21. Aluminium Sodium Polyhydroxy Monocarbonate Hexitol Complex	87. Chlorhexidine Acetate
22. Aluminium Sodium Silicate	88. Chlorhexidine Gluconate
23. Amaranth Solution, A.P.F.	89. Chlorobenzol Disulphonamide
24. Amaranth Solution, Compound, A.P.F.	90. Chloroxylenol
25. Amaranth Solution, B.P.C.	91. Cholera El Tor Combined Vaccine
26. Amino Acids	92. Cinnamon Spirit, B.P.C. 1949
27. Aminocaproic Acid	93. Cinnamon Water, Concentrated, B.P.C.
28. Ammonia Aromatic Spirit, B.P.C.	94. Clemizole Hydrochloride
29. Ammonia Solution Strong, B.P.C.	95. Clemizole Tannate
30. Ammonium Bicarbonate, B.P.C.	96. Clofibrate
31. Ammonium Bromide, B.P.C. 1963	97. Clopamide
32. Amphotericin B	98. Clorexolone
33. Angiotensin Amide	99. Clove, Concentrated Infusion, B.P.C. 1954
34. Antazoline Mesylate, B.P.C.	100. Coal Tar, B.P.C.
35. Antazoline Sulphate	101. Coal Tar Solution Strong, B.P.C.
36. Anti-Haemophilic Factor of Animal Origin	102. Cochineal Tincture, B.P. 1948
37. Attapulgite	103. Coconut Oil, B.P.C. 1949
38. Azathioprine	104. Codeine, B.P.C. 1954
39. Bacitracin Zinc	105. Copper Sulphate, B.P.C.
40. Beclamide	106. Creosote, B.P.C. 1959
41. Beeswax, Yellow, B.P.C.	107. Cudbear Tincture, A.P.F. 1947
42. Belladonna Suppository, B.P. 1948	108. Cyclothiazide
43. Benedict’s Solution, A.P.F.	109. Cycrimine Hydrochloride
44. Benzalkonium Chloride	110. Cymogran
45. Benzoin Compound Tincture, B.P.C.	111. Danthron
46. Benzoin Tincture, B.P.C.	112. Death Adder Antivenene
47. Benzoinated Lard, B.P.C. 1954	113. Debrisoquine
48. Benzylpenicillin in Oil	114. Demecarium Bromide
49. Bephenium Hydroxynaphthoate, B.P.C.	115. Deoxycortone Glucoside
50. Betamethasone Acetate	116. Deoxycortone Pivalate, B.P. 1963
51. Betamethasone Phosphate	117. Desferrioxamine
52. Bethanidine Sulphate	118. Deslanoside
53. Black Snake Antivenene	119. Dexamethasone Metasulphobenzoate
54. Biperiden Hydrochloride	120. Dexamethasone Sodium Phosphate
55. Bismuth Subgallate, B.P.C.	121. Dexchlorpheniramine Maleate
56. Bretylium Tosylate	122. Dextran
57. Brompheniramine Maleate	123. Dextriferron
53. Brown Snake Antivenene	124. Diazepam
59. Buchu Concentrated Infusion, B.P.C. 1954	125. Dibutyl Phthalate, B.P. 1963
60. Buclosamide	126. Diethanolamine Fusidate, B.P.C.
61. Butyl Aminobenzoate, B.P. 1953	127. Diethazine Hydrochloride, B.P. 1963
62. Cade Oil, B.P.C.	128. Dihydroergotamine Mesylate
63. Caffeine and Sodium Benzoate, B.P.C. 1954	129. Dihydroergotoxine Mesylate
64. Caffeine Citrate. B.P.C. 1959	130. Dihydrostreptomycin Sulphate, B.P. 1958
65. Cajuput Spirit, B.P. 1948	131. Dimethicone, B.P.C.
66. Calcium Di-Oxytetracycline	132. Dimethindene Maleate
67. Calcium Gluconogalactogluconate	133. Dioctyl Sodium Sulphosuccinate, B.P.C.
68. Calcium Phosphate, B.P.C.	134. Diphenylpyraline Hydrochloride
69. Calumba, Concentrated Infusion, B.P. 1948	135. Dipyridamole
70. Calumba Tincture. B.P. 1948	136. Disodium Stilboestrol Diphosphate
71. Capreomycin Sulphate	137. Ditophal
72. Capsicum Ointment, B.P.C.	138. Doxycyline Hyclate
73. Capsicum Tincture, B.P.C.	139. Ecothiopate Iodide
74. Carbamazepine	140. Entsufon
	141. Ephedrine, B.P.C.

Third Schedule—continued

142. Ergot, Liquid Extract, B.P. 1914
		204. Iron Polymaltose Complex
		205. Isoprenaline Hydrochloride
		206. Isopropamide Iodide
143. Erythrityl Tetranitrate		207. Isothipendyl Hydrochloride, B.P.C.
144. Erythromycin Ethyl Succinate		208. Kanamycin Sulphate, B.P.C.
145. Erythromycin Glucoheptonate		209. Kitasamycin
146. Erythromycin Lactobionate		210. Lanatoside-C
147. Ethacrynic Acid, B.P.C.		211. Lauryl Dimethyl Benzyl Ammonium Chloride
148. Ethanolamine, B.P.C.		212. Lavender Spike Oil, B.P.C.
149. Ethanolamine Oleate		213. Lead Subacetate Dilute Solution
150. Ether Nitrous Spirit, B.P.C. 1959		214. Lead Subacetate Strong Solution, B.P.C.
151. Ethoxzolamide		215. Lemon Tincture, B.P. 1958
152. Ethylidene Dicoumarin		216. Lincomycin Hydrochloride
153. Ethylnoradrenaline Hydrochloride		217. Lipopancreatin
154. Ethyloestrenol		218. Lobelia Ethereal Tincture, B.P.C.
155. Eucalyptol, B.P.C.		219. Lofenalac
156. Ferric Hydroxide		220. Lypressin
157. Ferrous Aminoacetosulphate		221. Magenta, B.P.C.
158. Ferrous Carbonate Saccharated, B.P.C. 1959		222. Magnesium-Aluminium Hydroxide
159. Ferrous Phosphate Compound, Syrup B.P.C.		223. Magnesium Hydroxide, B.P.C.
160. Flufenamic Acid		224. Mebhydrolin Napadisylate, B.P.C.
161. Flumethasone Pivalate		225. Meclastine Hydrogen Fumarate
162. Fluorouracil Sodium		226. Medroxyprogesterone Acetate
163. Fluphenazine Hydrochloride		227. Melphalan
164. Fluphenazine Enanthate		228. Mepenzolate Bromide
165. Folinic Acid		229. Mereaptomerin Sodium
166. Framycetin Sulphate		230. Mercuric Chloride, B.P.C.
167. Galactomin, Formula No. 17		231. Metaraminol Bitartrate
168. Galactomin, Formula No. 19		232. Metformin Hydrochloride
169. Gall and Opium Ointment, B.P.C. 1963		233. Methacycline
170. Gelsemium Tincture, B.P.C.		234. Methaqualone Hydrochloride
171. Gentamicin Sulphate		235. Methazolamide
172. Gentian Concentrated Compound Infusion, B.P. 1963		236. Methdilazine Hydrochloride
173. Ginger Syrup, B.P.C.		237. Methenamine Mandelate
174. Glucagon Hydrochloride		238. Methenolone Acetate
175. Glucose Indicator		239. Methotrexate
176. Glycerophosphate Compound Syrup, A.P.F.		240. Methoxamine Hydrochloride, B.P.C.
177. Glycopyrronium Bromide		241. Methsuximide
178. Glymidine		242. Methyclothiazide
179. Goat’s Milk, Dehydrated		243. Methylphenobarbitone, B.P.C. 1963
180. Goat’s Milk, Whole (Sterilised)		244. Methylprednisolone Acetate
181. Gramicidin		245. Methysergide Maleate
182. Guaiphenesin, B.P.C.		246. Metyrapone
183. Guanacline		247. Minafen
184. Haloperidol		248. Morphine Tartrate
185. Hamamelis Liquid Extract, B.P.C.		249. Myrrh Tincture, B.P.C.
186. Hexocyclium Methylsulphate		250. Nalidixic Acid. B.P.C.
187. Honey, Purified, B.P.C.		251. Nandrolone Hexoxyphenyl Propionate
188. Hydrargaphen		252. Natamysin
189. Hydrocyanic Acid, Dilute, B.P.C. 1954		253. Neomycin Undecenoate
190. Hydromorphone Hydrochloride		254. Nicotinyl Alcohol Tartrate
191. Hydroxyprogesterone		255. Nitrazepam
192. Hyoscine Methobromide		256. Nitromin
193. Hypophosphorous Acid, Dilute, B.P.C. 1963		257. Nutramigen
194. Hypromellose 4500		258. Octatropine Methylbromide
195. Idoxuridine		259. Oestradiol Dipropionate, B.P.C. 1954
196. Indomethacin		260. Oestrone, B.P.C. 1954
197. Insect Allergen Extract—Honey Bee		261. Oily Ophthalmic Vehicle, A.P.F. 1955
198. Insulin Injection, specially purified		262. Orange Peel Compound, Concentrated Infusion, B.P.C. 1954
199. Insulin Isophane Injection, specially purified		263. Orange Peel, Concentrated Infusion, B.P.C.
200. Insulin Injection, Special P (Pig)		264. Orange Syrup, B.P.C.
201. Invert Sugar		265. Orange Tincture, B.P.C.
202. Iodoform, B.P.C. 1954		266. Oxethazaine
203. Ipecacuanha and Opium Powder, B.P.C.		267. Oxycodone Pectinate
		268. Oxymel, B.P.C.

Third Schedule—continued

269. Oxymol of Squill, B.P.C.
	332. Salicylamide
	333. Secbutobarbitone Sodium
270. Oxymatholone	334. Senega, Concentrated Infusion, B.P.C. 1959
271. Oxyphenonium Bromide.	335. Senega, Concentrated Infusion, B.P.C. 1963
272. Oxytetracycline	336. Senna Compound Mixture, B.P.C. 1959
273. Oxytocin	337. Senna, Concentrated Infusion, B.P.C. 1959
274. Pancreatin Enzyme, U.S.N.F. XII	338. Senna Fruit Extract (Standardised)
275. Papaveresum, B.P.C	339. Siberian Fir Oil, B.P.C. 1949
276. Para-Aminosalicylic Acid	340. Silver Protein, B.P.C.
277. Paraben Ophthalmic Phosphate Buffer, A.P.F. 1955	341. Silver Protein Mild, B.P.C.
278. Paraben Ophthalmic Vehicle, A.P.F. 1955	342. Snake Bite Antivenene—Polyvalent
279. Paraffin Liquid Light, B.P.C. 1963	343. Sobee
280. Paramethasone Acetate	344. Sodium Folate
281. Pargyline Hydrochloride	345. Sodium Lactate
282. Pectin	346. Sodium Nitrate, B.P.C.
283. Penicillinase	347. Sodium Nitroprusside
284. Penicillin Benethamine, B.P.C.	348. Sodium Potassium Tartrate, B.P.C.
285. Pentaerythritol Tetranitrate, diluted, B.P.C.	349. Sodium Tauroglycocholate, B.P.C. 1954
286. Penthienate Methobromide	350. Sodium Thiosulphate
287. Peru Balsam B.P.C.	351. Sorbide Nitrate
288. Phenazone. B.P.C.	352. Sorbitol
289. Phenazopyridine Hydrochloride	353. Soyalac
290. Phenformin Hydrochloride	354. Spearmint Oil, B.P.C.
291. Phenirarmine Maleate	355. Spiramycin
292. Pheniramine Para-Aminosalicylate	356. Squill Tincture, B.P.C.
293. Phenol Ointment B.P. 1948	357. Stanolone
294. Phenoxymethylpenicillin, Benzathine	358. Stanozolol
295. Phenoxymethylpenicillin, Hydrabamine	359. Stearic Acid, B.P.C.
296. Phensuximide B.P.C.	360. Stone Fish Antivenene
297. Phenthimentonium	361. Strophanthus Tincture, B.P. 1948
298. Phenytoin, B.P.C.	362. Strychnine B.P.C. 1959
299. Phosphoric Acid Dilute, B.P. 1963	363. Sulphacetamide, B.P.C.
300. Phthalylsulphacetamide	364. Sulphaguanidine, B.P.C.
301. Physostigmine, B.P.C.	365. Sulphamelazine, B.P. 1958
302. Pilocarpine Hydrochloride	366. Sulphamethoxazole
303. Pipenzolate Methobromide	367. Sulphaphenazole, B.P.C.
304. Pituitary Hormone, Follicle-stimulating, Human	368. Sulphasalazine
305. Pituitary Hormone, Growth, Human	369. Sulphathiazole, B.P.C.
306. Pituitary (Posterior Lobe) Powdered, B.P.C.	370. Sulphurated Potash, B.P.C.
307. Polyoestradiol Phosphate	371. Sulphuric Acid, Dilute, B.P.C.
308. Polyvinyl Alcohol	372. Sulphur Sublimed, B.P.C.
309. Polythiazide	373. Surgical Cement
310. Potable Water	374. Surgical Cement Solvent
311. Potassium Chlorate, B.P.C.	375. Sustanon
312. Potassium Effervescent Tablet	376. Syrup Glucose Liquid, B.P.C. 1963
313. Potassium Perchlorate	377. Tacrine
314. Prednisolone Acetate	378. Taipan Antivenene
315. Prednisolone Sodium Succinate	379. Tar Ointment, B.P.C. 1959
316. Prednisolone Sodium Hemisulphate	380. Tartrazine, B.P.C. 1954
317. Prednisolone Tertiary Butyl Acetate	381. Terric, N8
318. Procarbazine Hydrochloride	382. Testosterone Enanthate
319. 1,2-Propanediol Diacetate	383. Tetracosactrin
320. Prosobee	384. Tetracycline, B.P.C.
321. Protriptyline Hydrochloride	385. Thiethylperazine Maleate
322. Pumilio Pine Oil, B.P.C.	386. Thioridazine
323. Pyridine Aldoxime Methiodide	387. Thiotepa
324. Quillaia Tincture, B.P.C.	388. Thonzonium Bromide
325. Quinethazone	389. Thonzylamine Hydrochloride
326. Quinedine Bisulphate	390. Thyrotropin
327. Raspberry Syrup B.P.C.	391. Tiemonium Iodide
328. Rauwolfia Alkaloids	392. Tiger Snake Antivenene
329. Red Back Spider Antivenene	393. Titanium Dioxide, B.P.C.
330. Rolitetracycline	394. Tolazamide
331. Rosemary Oil, B.P.C.	395. Tolu Tincture, B.P.C. 1959

Third Schedule—continued

396. Tragacanth, Indian (Gum Karaya)	409. Urethane, B.P. 1963
397. Tragacanth Mucilage	410. Vadrine
398. Trasylol	411. Valerian Ammoniated Tincture, B.P.C. 1963
399. Tretamine	412. Vanillin
400. Triacetyloleandomycin	413. Vasopressin Tannate
401. Tridihexethyl Chloride	414. Velactin
402. Triethanolamine, B.P.C.	415. Vinblastine Sulphate
403. Triglyde	416. Vincristine Sulphate
404. Trimeprazine Tartrate, B.P.C.	417. Vinegar of Squill, B.P.C.
405. Tripelennamine Hydrochloride	418. Vitamin A
406. Trolnitrate Phosphate	419. Vitamin D
407. Typhoid Vaccine	420. Zinc Gelatin, B.P.C.
408. Typhoid and Cholera El Tor Combined Vaccine	421. Disodium Cromoglycate

_______________

Fourth Schedule

Regulation 12.

Additives

1. Acetone, B.P.C.	13. Dilute Alcohols, B.P.
2. Alcohol (95%), B.P.	14. Ether Anaesthetic, B.P.
3. Arachis Oil, B.P.	15. Honey—Purified
4. Amethocaine Hydrochloride, B.P.	16. Maize Oil, B.P.
5. Camphor, B.P.	17. Olive Oil, B.P.
6. Caraway Oil, B.P.C.	18. Pilocarpine Hydrochloride
7. Carmine Solution, A.P.F.	19. Saccharin Sodium, B.P.
8. Citronella Oil, B.P.C.	20. Sodium Thiosulphate, B.P.C.
9. Chloroform, B.P.	21. Solution of Burnt Sugar, B.P.C. 1959
10. Cottonseed Oil, B.P.	22. Spirit, Methylated, Industrial
11. Dextrose, B.P.	23. Xylene, B.P.C. 1949
12. Dextrose Monohydrate, B.P.

___________

FIFTH SCHEDULE

Regulation 14.

Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
1	Acetylcholine Chloride with Mannitol, B.P..	Any disease or condition in a patient receiving treatment in or at an approved hospital
2	Acetylcysteine....................	Fibrocystic disease
3	(1) Aspirin Tablets, B.P...............	Any disease or condition in a pensioner
	(2) Soluble Aspirin Tablets, B.P.........
	(3) Aspirin with Paracetamol and Caffeine Tablets
	(4) Aspirin with Codeine Phosphate and Pentobarbitone Sodium Tablets
4	Acrylic Resin.....................	Ileostomy or colostomy conditions
5	Albumaid XP.....................	With the written authority of the Director-General—
		Phenylketonuria
6	Aldosterone......................	With the written authority of the Director-General, treatment of an acute crisis in—
		Addison’s disease
		Salt-losing congenital adrenal hypoplasia
7	Allopurinol......................	Chronic gout not responding to other pharmaceutical benefits
		Gout associated with renal failure
8	Aloxiprin........................	Any disease or condition in a pensioner
9	Aluminium Acctylsalicylate Tablet.......	Any disease or condition in a pensioner

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
10	Aminocaproic Acid.................	Any disease or condition in a patient receiving treatment in or at an approved hospital
11	(1) Amitriptyline Hydrochloride........	Any disease or condition in a pensioner
	(2) Amitriptyline Tablets, B.P..........	Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Amitriptyline Hydrochloride or Amitriptyline Tablets, B.P.
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
12	Amphotericin B...................	Systemic fungal infection
13	(1) Ampicillin Capsules, B.P...........	With the written authority of the Director-General—
	(2) Ampicillin Injections, Tablets and Suspension	Gram-negative infections in pregnant women
	(2) Ampicillin Injections, Tablets and Suspension	Infections in children, in which penicillin and sulphonamides are not effective
		Infections where positive bacteriological evidence confirms that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case
		Acute infections threatening the life of a patient where clinical evidence shows that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case
		Chronic bronchitis complicated by emphysema where other therapeutic agents have failed
14	Angiotensin Amide.................	Any disease or condition in a patient receiving treatment in or at an approved hospital
15	Ascorbic Acid Tablets, B.P............	Any disease or condition in a pensioner
16	(1) Azathioprine...................	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Beclamide....................
17	Benzoin Compound Tincture, B.P.C. aerosol spray	Ileostomy or colostomy conditions
18	Benzylpenicillin Injection, 5,000,000 units.	Bacterial endocarditis or septicaemia
19	(1) Benzylpenicillin Tablets, B.P........	Prevention of recurrent streptococcal infections, including rheumatic fever
	(2) Benzylpenicillin Capsules..........
20	Benzylpenicillin Injection, 10,000,000 units	Bacterial endocarditis or septicaemia
	Benzylpenicillin Injection, 10,000,000 units	Gastrointestinal surgery
21	(1) Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to Streptococcus faecalis or Streptococcus viridans
	(2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
22	(1) Betamethasone Syrup ............	With the written authority of the Director-General—
	(2) Betamethasone Tablets ............	Acquired haemolytic anaemia
		Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Acute phase of herpes zoster
		Acute rheumatic carditis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
22	(1) Betamethasone Syrup	Adrenogenital syndrome
	(2) Betamethasone Tablets—continued—	Agranulocytosis
	(2) Betamethasone Tablets—continued—	Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral oedema
		Cerebral tumors
		Cranial arteritis
		Cushing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Nodular non-suppurative panniculitis (Christian-Weber disease)
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Seleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Splenic neutropenia
		Status asthmaticus

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
22	(1) Betamethasone Syrup	Steroid therapy prior to operation for those patients under steroid therapy
	(2) Betamethasone Tablets—continued—
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Systemic lupus erythematosus
		Sympathetic ophthalmitis
		Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
		With the written authority of the Director-General, for the treatment, in conjunction with other therapy—
		(a) of chronic or recurrent asthma in the case of a patient whose asthma interfere seriously with his normal activities of life; or
		(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn
23	Betamethasone Acetate and Betamethasone Alcohol Injection	Intra-articular use
24	Betamethasone Sodium Phosphate Injection, B.P.	Intra-articular use
25	Betamethasone Valerate with Clioquinol	For the treatment of diseases of the ear
26	Buclosamide with Salicylic Acid	For the treatment of diseases of the ear
27	Buclosamide, Salicylic Acid and Hydrocortisone Acetate	For the treatment of diseases of the ear
28	Busulphan Tablets, B.P................	Treatment in neoplastic disease
29	(1) Calciferol Tablets, Strong, B.P.	Any disease or condition in a pensioner
	(2) Calciferol, B.P...................	With the written authority of the Director-General—
		Hypoparathyroidism
		Chronic hypoparathyroid tetany
		Post Gastrectomy osteomalacia
		Vitamin D-resistant rickets
30	Calcium Aminosalicylate..............	Tuberculosis
31	Capreomycin Sulphate...............	Any disease or condition in a patient receiving treatment in or at an approved hospital
32	Carbamazepine....................	Epilepsy
		Trigeminal neuralgia
33	Carbenicillin......................	Any disease or condition in a patient receiving treatment in or at an approved hospital
34	(1) Carbenoxolone Sodium.............	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Cephaloridine...................
35	Charcoal Tablets...................	Ileostomy or colostomy conditions
36	Clofibrate .. .. ..	With the written authority of the Director-General, for the treatment of hypercholesterolaemia with xanthomata
37	Chlorambucil Tablets, B.P.............	Treatment in neoplastic disease
38	Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions
39	Chloramphenicol Capsules, B.P.	Bacterial meningitis
		Haemophilus influenzae infections
		Intra-ocular infections
		Rickettsial infections
		Salmonella septicaemia
		Typhoid and paratyphoid
		Other serious infections sensitive only to Chloramphenicol Capsules, B.P.

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
40	(1) Chloramphenicol Injections.......	Bacterial meningitis
	(2) Chloramphenicol Tablets........	Haemophilus influenzae infections
	(3) Chloramphenicol Oral Suspension	Intra-ocular infections
	(3) Chloramphenicol Oral Suspension	Rickettsial infections
		Salmonella septicaemia
		Typhoid and paratyphoid
		Other serious infections sensitive only to Chloramphenicol Injections, Chloramphenicol Tablets or Chloramphenicol Oral Suspension
41	Chlorotrianisene Tablets...........	Carcinoma of the prostate
42	(1) Chlorpromazine Hydrochloride, B.P.	Any disease or condition in a pensioner
	(1) Chlorpromazine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Chlorpromazine Injection, B.P. (3) Chlorpromazine Tablets, B.P.
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Hydrochloride Injection, B.P., or Chlorpromazine Tablets, B.P.
		With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		Huntington’s chorea
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
43	Chlortetracycline Capsules, B.P.	Brucellosis
		Herpes zoster ophthalmicus
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
44	(1) Cloxacillin Sodium, B.P.........	Any disease of condition in a patient receiving treatment in or at an approved hospital
	(2) Cloxacillin Capsules, B.P........
45	(1) Codeine Phosphate with Aspirin Soluble Tablets	Any disease or condition in a pensioner
	(2) Codeine Phosphate with Aspirin Tablets
	(3) Codeine Phosphate with Aspirin and Paracetamol Soluble Tablets
	(4) Codeine Phosphate with Aspirin, Paracetamol and Caffeine Tablets
46	Cod Liver Oil Emulsion............	Any disease or condition in a child under the age of twelve years or in a pensioner
47	Colistin Sulphomethate Injection, B.P.	Pyocyaneus infection and Gram-negative infections where no other drug is effective
48	(1) Corticotropin Injection, B.P.	With the written authority of the Director-General—
	(2) Corticotrophin Gelatin Injection, B.P.	The prevention of side effects of corticosteroid therapy
	(3) Corticotrophin Zinc Hydroxide Injection, B.P.	Acquired haemolytic anaemia
	(3) Corticotrophin Zinc Hydroxide Injection, B.P.	Acute disseminated encephalomyelitis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
48	Corticotrophin Injection, B.P.	Acute exacerbations of multiple sclerosis
	(2) Corticotrophin Gelatin Injection, B.P.	Acute exfoliative dermatitis
	(2) Corticotrophin Gelatin Injection, B.P.	Acute phase of Bell’s Palsy
	(3) Corticotrophin Zinc Hydroxide Injection, B.P.—continued	Acute rheumatic carditis
	(3) Corticotrophin Zinc Hydroxide Injection, B.P.—continued	Addison’s disease or other forms of adrenocortical hypoplasia
		Adrenogenital syndrome
		Agranulocytosis
		Behcet’s syndrome
		Cranial arteritis
		Cushing’s syndrome including hyperadrenocorticalism
		Dermatomyositis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Hypsarrhythmia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Salaam convulsions
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Systemic lupus erythematosus
		Sympathetic ophthalmitis
		Temporal arteritis
		Thrombocytopenic purpura

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
48	(1) Corticotrophin Injection, B.P.	Tropical and non-tropical sprue and forms of malabsorption associated with those diseases
	(2) Corticotrophin Gelatin Injection, B.P.
	(3) Corticotrophin Zinc Hydroxide Injection, B.P.—continued	Type II nephritis
49	Cortisone Injection, B.P. ..	Ulcerative colitis proven by sigmoidoscopy or radiological report
		With the written authority of the Director-General—
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Anaemia, acquired haemolytic
		Addison’s disease
		Adrenocortical hypoplasia
		Adrenalectomy, total
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral tumours and cerebral oedema
		Cranial arteritis
		Cushing’s syndrome, including hyperadrenocorticalism
		Dermatitis, acute exfoliative
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Encephalomyelitis, acute disseminated
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Oedema of the spinal cord following trauma or infection
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary cosinophilia
		Purpura, Henoch’s
		Purpura, thrombocytopenic
		Regional ileitis (Crohn’s disease)

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
49	Cortisone Injection, B.P.—continued	Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Rheumatic carditis, acute
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following
		X-ray therapy
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation in patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in a child under the age of sixteen years
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Treatment of malignancy in conjunction with radiotherapy or chemotherapy
		Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
50	Cortisone Tablets, B.P...............	With the written authority of the Director-General—
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Anaemia, acquired haemolytic
		Addison’s disease
		Adrenocortical hypoplasia
		Adrenalectomy, total
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral tumours and cerebral oedema
		Cranial arteritis
		Cushing’s syndrome, including hyperadrenocorticalism
		Dermatitis, acute exfoliative
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Encephalomyelitis, acute disseminated
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty

Fifth Schedule—continued

	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whoso treatment it may be prescribed) for supply under Part VII. of the Act
50	Cortisone Tablets, B.P.—continued	Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Oedema of the spinal cord following trauma or infection
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Purpura, thrombocytopenic
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Rheumatic carditis, acute
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation in patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in a child under the age of sixteen years
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Treatment of malignancy in conjunction with radio therapy or chemotherapy
		Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
		With the written authority of the Director-General, for the treatment, in conjunction with other therapy—
		(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or
		(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn
51	Cyanocobalamin Injection, B.P...	Established megalocytic anaemia
		Neuroblastoma
		Sub-acute combined degeneration of the cord
		Treatment in post-gastrectomy
52	Cymogran.................	With the written authority of the Director-General, phenylketonuria

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
53	(1) Cycloserine Tablets, B.P.........	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Cycloserine Capsules, B.P.
54	(1) Demethylchlortetracycline Capsules, B.P.	Brucellosis
	(1) Demethylchlortetracycline Capsules, B.P.	Intestinal amoebiasis
	(2) Demethylchlortetracycline Hydrochloride Oral Paediatric Drops and Oral Suspension	Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
55	Demethylchlortetracycline Hydrochloride with Nystatin	Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis
		A second or repeated course of broad spectrum antibiotic therapy for—
		Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
56	(1) Deodorant Detergent Solution (Terric N.8 with Spearmint Oil and Cetrimide)	Ileostomy or colostomy conditions
	(2) Deodorant Detergent Solution (Lauryldimethyl Benzyl Ammonium Chloride and Terric N.8)
	(1) Deoxycortone Aqueous Injections

57		Addison’s disease
	(2) Deoxycortone Acetate Injection, B.P.	Adrenalectomy, total
	(3) Deoxycortone Trimethylacetate Injection, B.P.
	(4) Deoxycortone Acetate Implants, B.P.
	(5) Deoxycortone Acetate Tablets
58	Desferoxamine	Any disease or condition in a patient receiving treatment in or at an approved hospital
59	Dexamethasone Tablets, B.P.........	With the written authority of the Director-General—
		Acquired haeomolytic anaemia
		Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Acute phase of herpes zoster
		Acute rheumatic carditis
		Adrenogenital syndrome
		VAgranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
59	Dexamethasone Tablets, B.P.—continued	Cerebral oedema
	Dexamethasone Tablets, B.P.—continued	Cerebral tumors
		Cranial arteritis
		Cashing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Nodular nonsuppurative panniculitis (Christian-Weber disease)
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilic
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
59	Dexamethasone Tablets, B.P.—continued	Sympathetic ophthalmitis
	Dexamethasone Tablets, B.P.—continued	Systemic lupus erythematosus
		Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
60	Dexamethasone Sodium Phosphate Injections	Intra-articular use
	Dexamethasone Sodium Phosphate Injections	Cerebral oedema
61	(1) Dextromoramide Tablets......	Treatment in neoplastic disease
	(2) Dextromoramide Injection
62	Diazepam Injection............	Cardioversion
		Endoscopic examination
		Epilepsy
		Minor operative procedure
		Premedication induction of anaesthesia
		Upper motor neurone lesion
63	Diazepam Syrup and 10 mg. Tablet	Epilepsy
		Upper motor neurone lesion
64	Diazepam Tablets 2 mg. and 5 mg.	Epilepsy
		Upper motor neurone lesion
		Treatment in multiple sclerosis
		Stiff-man syndrome
65	Dienoestrol Cream.............	Any disease or condition in a pensioner
66	Dienoestrol Tablets, B.P.........	Carcinoma of the prostate
		Mammary carcinoma
		Any disease or condition in a pensioner
67	Dihydroergotoxine Mesylate......	For the treatment of patients who have suffered an attack of paralytic poliomyelitis
	(1) Tablets
	(2) Injections
68	Dihydrotachysterol.............	Parathyroid deficiency
69	Diloxanide Furoate Tablets, B.P....	Amoebic dysentry
70	Dimethicone.................	Ileostomy or colostomy conditions
71	Dimethicone Creams...........	Use with surgical appliances
72	Dioctyl Sodium Sulphosuccinate with Danthron	Any disease or condition in a pensioner
73	Disodium Stilboestrol Diphosphate	Carcinoma of the prostate
74	Ditophal....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
75	Doxycycline Hyclate..........	Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
76	(1) Erythromycin..............	Brucellosis
	(2) Erythromycin ethyl succinate suspension	Intestinal amoebiasis
	(2) Erythromycin ethyl succinate suspension	Leptospirosis
	(3) Erythromycin ethyl succinate chewable tablet	Lymphogranuloma venereum
	(3) Erythromycin ethyl succinate chewable tablet	Mycoplasma pneumoniae (Eaton’s Agent)
		Psittacosis
		Rickettsial infections
		Staphylococcal septicaemia or staphylococcal pneumonia

Fifth Schedule—continued

First Column	Second column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
76	(1) Erythromycin..............	Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
	(2) Erythromycin ethyl succinate suspension
	(3) Erythromycin ethyl succinate chewable tablet—continued
	(3) Erythromycin ethyl succinate chewable tablet—continued	Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
77	Ethinyloestradiol Tablets, B.P.....	Any disease or condition in a pensioner
		Hereditary telangiectasis
		Pre-menopausal castration syndrome
		Turner’s syndrome
78	Ethionamide.................	Tuberculosis
79	Ethisterone Tablets, B.P.........	Turner’s syndrome
80	Ethyloestrenol................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
		Intermittent use for patients on long term treatment with corticosteroids
		Post-gastrectomy osteomalacia
81	Fludrocortisone Tablets, B.P......	Addison’s disease
		Adrenocortical hypoplasia
		Total adrenalectomy
82	Flufenamic Acid..............	Any disease or condition in a patient receiving treatment in or at an approved hospital
83	Flumethasone Pivalate and Clioquinol	For the treatment of diseases of the car
84	Fluorouracil Sodium............	Treatment in neoplastic disease
85	Fluoxymesterone Tablets, B.P.....	Castration syndrome (male)
		Mammary carcinoma
		With the written authority of the Director-General—
		Aplastic anaemia
		Intermittent use for corticosteroid-induced osteoporosis
		Primary refractory anaemias
86	Fluphenazine Enanthate.........	Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
		Fluphenazine Enanthate
		Fluphenazine Hydrochloride
		With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		Huntington’s chorea
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
87	Fluphenazine Hydrochloride.......	Any disease or condition in a pensioner
		Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
		Fluphenazine Enanthate
		Fluphenazine Hydrochloride
		With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		Huntington’s chorea
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
88	(1) Folic Acid Injection..........	Macrocytic anaemia
	(2) Folic Acid Tablets, B.P........	Sprue or the sprue-like syndrome
		Proven folic acid deficiency
89	Folinic Acid..................	Any disease or condition in a patient receiving treatment in or at an approved hospital
90	Framycetin Sulphate Tablets.......	Bowel sterilization preparatory to major surgery
91	Fusidic Acid (Sodium Salt or Diethanolamine Salt)	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic
92	Galactomin Formula No. 17.......	With the written authority of the Director-General—
		Galactosaemia
		Conditions needing an extreme restriction of lactose in the patient’s diet, under the age of four years
93	Galactomin Formula No. 19.......	With the written authority of the Director-General—
		Glucose-galactose malabsorption
94	Gentamicin Sulphate............	Any disease or condition in a patient receiving treatment in or at an approved hospital
95	Goat’s Milk, Dehydrated.........	With the written authority of the Director-General, cow’s milk allergy in children under the age of four years
96	Goats Milk, Whole (Sterilized).....	With the written authority of the Director-General—cow’s milk allergy in children under the age of four years
97	Griseofulvin Tablets, B.P.........	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination
98	Guanacline Tablets.............	Any disease or condition in a patient receiving treatment in or at an approved hospital
99	Halibut Liver Oil Capsules........	Any disease or condition in a pensioner
100	Haloperidol..................	Any disease or condition in a pensioner
		Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Haloperidol

Fifth Schedule—continued

First Colomn	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
100	Haloperidol—continued	With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		Huntington’s chorea
		The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
101	(1) Hexachlorophane with Chloroxylenol	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Hexachlorophane with Entsufon
	(3) Hexachlorophane with Lissapol
	(4) Hexachlorophane in Soap Solution
102	Hydrocortisone Injection	With the written authority of the Director-General—
		Acquired haemolytic anaemia
		Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Acute rheumatic carditis
		Addison’s disease or other forms of adrenocortical hypoplasia
		Adrenalectomy, total
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral oedema
		Cerebral tumors
		Cranial arteritis
		Cushing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
102	Hydrocortisone Injection—continued	Nephrosis or nephrotic syndrome
	Hydrocortisone Injection—continued	Neuromyelitis optica
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
103	Hydrocortisone Acetate Injection, B.P.	Intra-articular use
104	Hydrocortisone Acetate, B.P. with Neomycin Sulphate, B.P. Ear drops and ear ointment	For the treatment of diseases of the ear
105	Hydrocortisone with 1,2-Propanediol Diacetate and Acetic Acid	For the treatment of diseases of the ear
106	Hydrocortisone Sodium Succinate Injection	Acute adrenal failure due to medical or surgical crisis
	Hydrocortisone Sodium Succinate Injection	Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy
		Stevens-Johnson syndrome
107	Hydrocortisone Ear Drops.........	For the treatment of diseases of the ear
108	Hydroxocobalamin Injection, B.P.	Established megalocytic anaemia
		Neuroblastoma
		Sub-acute combined degeneration of the cord
		Treatment in post-gastrectomy
109	Hydroxyprogesterone............	Endometrial carcinoma
		Progesterone deficiency proven by hormonal assay of lateral wall smear
110	Idoxuridine..................	Infections caused by Herpes Simplex Virus

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
111	(1) Imipramine Tablets, B.P.......	Any disease or condition in a pensioner
	(2) Imipramine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Imipramine Hydrochloride, B.P. or Imipramine Tablets, B.P.
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
112	Indomethacin Capsules...........	Acute attacks of gout
		Ankylosing spondylitis
		Psoriatic arthritis
		Reiter’s syndrome
		Rheumatoid arthritis or osteoarthritis not responding to salicylates
113	Indomethacin Suppositories ..	For the treatment of the following conditions in persons who cannot tolerate oral indomethacin—
		Acute attacks of gout
		Ankylosing spondylitis
		Osteoarthritis not responding to salicylates
		Psoriatic arthritis
		Reiter’s syndrome
		Rheumatoid arthritis not responding to salicylates
114	Influenza Vaccine..............	For the treatment of pensioners only
115	Insect Allergen Extract—Honey Bee	For the treatment of severe constitutional reaction to bee stings
116	Isoniazid Tablets, B.P...........	Tuberculosis
117	Isoprenaline Hydrochloride Tablets	For long-term use in patients suffering from Stokes-Adams’ seizures due to heart block
118	Kanamycin Sulphate Capsules, Injections and Oral Solution	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic
119	Kitasamycin..................	Any disease or condition in a patient receiving treatment in or at an approved hospital
120	Levorphanol Tartrate............	Obstetrical use
		Severe intractable pain
121	Lignocaine Injection, B.P.........	Cardiac arrhythmias
122	Lincomycin Hydrochloride........	Gram positive coccal infections where these cannot be safely and effectively treated with penicillin
		Osteomyelitis
123	Liothyronine Tablets, B.P........	Myxoedema
124	Lipopancreatin................	Fibrocystic disease
		Pancreatico-duodenectomy
		Pancreatic steatorrhea
125	Lofenalac...................	With the written authority of the Director-General, phenylketonuria
126	Medroxyprogesterone Acetate Tablets 2.5 mg. and 10 mg.	Adenocarcinoma of the uterus (endometrial carcinoma)
127	Medroxyprogesterone Acetate Tablets 100 mg.	Adenocarcinoma of the body of the uterus
	Medroxyprogesterone Acetate Tablets 100 mg.	Hypernephroma
128	Medroxyprogesterone Acetate Injections	Adenocarcinoma of the uterus (endometrial carcinoma)
		Hypernephroma
		Progesterone deficiency proven by hormonal assay of lateral wall smear

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
129	Melphalan..................	Treatment in neoplastic disease
130	Mercaptopurine Tablets, B.P.....	Allergic angiitis
		Treatment in neoplastic disease
		Lupus erythematosus
		Nephrosis or nephrotic syndrome
		Periarteritis
131	Methacycline................	Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
132	(1) Methandienone Tablets, B.P.	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
	(2) Methenolone Acetate........

		Intermittent use for patients on long-term treatment with corticosteroids
133	Methicillin Injection, B.P........	Proven or suspected staphylococcal septicaemia
134	Methotrexate Tablets..........	Treatment in neoplastic disease
135	Methotrexate Injections.........	Any disease or condition in a patient receiving treatment in or at an approved hospital

136	(1) Methylprednisolone Tablets, B.P.	With the written authority of the Director-General—
	(1) Methylprednisolone Tablets, B.P.	Acquired haemolytic anaemia
	(2) Methylprednisolone Capsules	Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Acute phase of herpes zoster
		Acute rheumatic carditis
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral oedema
		Cerebral tumors
		Cranial arteritis
		Cushing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry

		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be proscribed) for supply under Part VII. of the Act
136	(1) Methylprednisolone Tablets, B.P.	Keratoplasty
	(1) Methylprednisolone Tablets, B.P.	Leucine sensitive hypoglycaemia
	(2) Methylprednisolone Capsules—continued	Leukaemia
	(2) Methylprednisolone Capsules—continued	Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Malignant exophthalmos
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Nodular nonsuppurative panniculitis (Christian-Weber disease)
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary cosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proved by sigmoidoscopy or radiological report
		With the written authority of the Director-General, for the treatment, in conjunction with other therapy—
		(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or
		(b) of a severe asthmatic whose cute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn
137	(1) Methyl testosterone Tablets, B.P.	Castration syndrome (male)
	(1) Methyl testosterone Tablets, B.P.	Klinefelter Reifenstein Albright syndrome
	(2) Methyltestosterone, B.P.	Mammary carcinoma

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
138	Methysergide Maleate............	With the written authority of the Director-General, for the treatment of severe recalcitrant migraine where other treatment has failed
139	Metyrapone..................	Any disease or condition in a patient receiving treatment in or at an approved hospital
140	Minafen.....................	With the written authority of the Director-General, phenylketonuria
141	Morphine Sulphate, B.P. with Tacrine Tablets	Severe intractable pain
142	Mustine Hydrochloride Injection	Treatment in neoplastic disease
143	Nalidixic Acid.................	Urinary tract infections in which sulphonamides are not effective
144	Nandrolone Hexoxyphenyl Propionate	Mammary carcinoma
	Nandrolone Hexoxyphenyl Propionate	With the written authority of the Director-General—
		Intermittent use or corticosteroid-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteroids
145	Nandrolone Phenylpropionate Injection, B.P.	Mammary carcinoma
	Nandrolone Phenylpropionate Injection, B.P.	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
146	Nandrolone Decanoate...........	Mammary carcinoma
		With the written authority of the Director-General—
		Intermittent use for corticosteroid-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteroids
		Severe osteoporosis due to proven pancreatitis
147	(1) Natamycin Oral Tablets........	Monilia infections
	(2) Natamycin Suspension
148	Neomycin Sulphate Powder........	With the written authority of the Director-General, intermittent use by inhalation in fibrocystic disease
149	Neomycin Sulphate, B.P. with Gramicidin, Thonzonium Bromide, Thonzylamine Hydrochloride and Hydrocortisone Acetate, B.P.	For the treatment of diseases of the ear
150	Neomycin Tablets, B.P...........	Bowel sterilization preparatory to major surgery
		Portal-systemic encephalopathy
151	Neomycin Undecenoate with Bacitracin Zinc	For the treatment of diseases of the ear
152	Nicotinic Acid Tablets, B.P........	Any disease or condition in a pensioner
153	Nitrazepam...................	Myoclonic epilepsy
154	(1) Nitrofurantoin Tablets, B.P......	Urinary tract infections
	(2) Nitrofurantoin Oral Suspension
155	Nitromin....................	Treatment in neoplastic disease
156	(1) Nortriptyline Hydrochloride, B.P.	Any disease or condition in a pensioner
	(1) Nortriptyline Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Nortriptyline Tablets, B.P.
	(3) Nortriptyline Capsules, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Nortriptyline Hydrochloride, B.P., Nortriptyline Tablets, B.P. or Nortriptyline Capsules, B.P.

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
156	(1) Nortriptyline Hydrochloride, B.P.	With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
	(2) Nortriptyline Tablets, B.P.
	(3) Nortriptyline Capsules, B.P.—continued
157	Nutramigen.................	With the written authority of the Director-General—
		Cow’s milk allergy in children under the age of four years
		Galactosaemia
		Lactose intolerance
		Fibrocystic disease of the pancreas
158	Nystatin Tablets, B.P..........	Monilia infections
159	Oreiprenaline Sulphate Injection...	Any disease or condition in a patient receiving treatment in or at an approved hospital
160	Oxycodone Pectinate..........	Treatment in neoplastic disease
161	Oxymetholone...............	With the written authority of the Director-General—
		Aplastic anaemia
		Primary refractory anaemias
162	(1) Oxytetracycline Capsules, B.P.	Brucellosis
	(2) Oxytetracycline Tablets, B.P.	Intestinal amoebiasis
	(3) Oxytetracycline Injections	Leptospirosis
	(4) Calcium di-Oxytetracycline Oral Suspension	Lymphogranuloma venereum
	(4) Calcium di-Oxytetracycline Oral Suspension	Psittacosis
	(5) Calcium di-Oxytetracycline Paediatric Drops	Rickettsial infections
	(5) Calcium di-Oxytetracycline Paediatric Drops	Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
163	Oxytetracycline Hydrochloride with a buffering agent and Nystatin	Broad spectrum antibiotic therapy of prematura infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis
		A second or repeated course of broad spectrum antibiotic therapy for—
		Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
164	(1) Pancreatin, B.P............	Fibrocystic disease
	(2) Pancreatin Enzyme U.S.N.F. XII	Pancreatico-duodenectomy
	(2) Pancreatin Enzyme U.S.N.F. XII	Pancreatic steatorrhoea
165	Para-Aminosalicylic Acid.......	Tuberculosis
166	(1) Paracetamol Suspension......	Any disease or condition in a pensioner
	(2) Paracetamol Tablets, B.P.....
167	Paracetamol with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
168	Paramethasone Acetate.........	With the written authority of the Director-General—
		Acquired haemolytic anaemia
		Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
168	Paramethasone Acetate—continued	Acute phase of herpes zoster
		Acute rheumatic carditis
		Addison’s disease or other forms of adrenocortical hypoplasia
		Adrenalectomy, total
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral oedema
		Cerebral tumors
		Cranial arteritis
		Cushing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillin-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hanson’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary cosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
168	Paramethasone Acetate—continued	Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
169	(1) Paraffin Liquid Emulsion......	Any disease or condition in a pensioner
	(2) Paraffin Liquid Emulsion with Phenolphthalein
170	Pargyline Hydrochloride........	Any disease or condition in a patient receiving treatment in or at an approved hospital
171	Penicillamine................	With the written authority of the Director-General—
		Cystinosis
		Cystinuria with calculus formation
		Treatment of cold agglutinin haemoglobinuria
		Acute heavy metal intoxication
		Wilson’s disease (hepatolenticular degeneration)
172	Pethidine Hydrochloride with Levallorphan Tartrate	Obstetrical use
173	(1) Phenylbutazone Tablets, B.P.	Rheumatoid arthritis or osteoarthritis not responding to salicylates
	(2) Phenylbutazone Capsules......
		Acute attacks of gout
		Ankylosing spondylitis
		Psoriatic arthritis
		Reiter’s syndrome
174	(1) Phenylbutazone Suppositories	For the treatment of the following conditions in persons who cannot tolerate Phenylbutazone Tablets, B.P. and Phenylbutazone Capsules:—
	(2) Phenylbutazone Injection......

		Acute attacks of gout
		Ankylosing spondylitis
		Psoriatic arthritis
		Reiter’s syndrome
		Rheumatoid arthritis or osteoarthritis not responding to salicylates
175	Phytomenadione Injection, B.P.	Antidote to anticoagulants
176	Phytomenadione Injection, B.P., 1 mg.	Antidote to anticoagulants
	Phytomenadione Injection, B.P., 1 mg.	Suspected cerebral trauma of the new born
		Haemorrhagic disease of the new born
177	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
178	Polymyxin B. Sulphate Powder....	With the written authority of the Director-General, intermittent use by inhalation in fibrocystic disease
179	Polymyxin B. Sulphate Neomycin Sulphate and Hydrocortisone	For the treatment of diseases of the ear
180	Polymyxin B. Sulphate with Bacitracin and Neomycin Sulphate	For the treatment of diseases of the ear
181	Polyoestradiol Phosphate........	Carcinoma of the prostate
182	Prednisolone Sodium Phosphate Retention Enema and Suppository	With the written authority of the Director-General—
		Ulcerative colitis proven by sigmoidoscopy or radiological report
		Proctitis proven by sigmoidoscopy

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
183	Prednisolone Tablets, B.P........	With the written authority of the Director-General—
		Acquired haemolytic anaemia
		Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Acute phase of herpes zoster
		Acute rheumatic carditis
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral oedema
		Cerebral tumors
		Cranial arteritis
		Cushing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypcrcalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Malignant exophthalmos
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Nodular nonsuppurative panniculitis (Christian-Weber disease)
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
183	Prednisolone Tablets, B.P.—continued	Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
		With the written authority of the Director-General, for the treatment, in conjunction with other therapy—
		(a) of chronic or recurrent asthma in the case of a patient whose asthma interfers seriously with his normal activities of life; or
		(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn
184	Prednisolone Methyl Acetate Injection	Intra-articular use
185	(1) Prednisolone Acetate Injection	Intra-articular use
	(2) Prednisolone Tertiary Butyl Acetate Injection
186	Prednisolone Sodium Phosphate and Neomycin Sulphate	For the treatment of diseases of the ear
187	Prednisolone Sodium Succinate....	Acute adrenal failure due to medical or surgical crisis
		Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy
		Stevens-Johnson syndrome
188	Prednisone Tablets, B.P.........	With the written authority of the Director-General—
		Acquired haemolytic anaemia
		Acute disseminated encephalomyelitis
		Acute exfoliative dermatitis
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Acute phase of herpes zoster
		Acute rheumatic carditis
		Adrenogenital syndrome
		Agranulocytosis
		Angioneurotic oedema
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral oedema
		Cerebral tumors
		Cranial arteritis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
188	Prednisone Tablets, B.P.—continued	Cushing’s syndrome including hyperadrenocorticalism
		Dermatitis herpetiformis
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Hypoplastic anaemia
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial keratitis due to syphilis or vernal
		conjunctivitis
		Keratoplasty
		Leucine sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Malignancy treatment in conjunction with radiotherapy or chemotherapy
		Malignant exophthalmos
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome
		Neuromyelitis optica
		Nodular nonsuppurative panniculitis (Christian-Weber disease)
		Oedema of the spinal cord following trauma or infections
		Optic neuritis following removal of tumors of the brain
		Panhypopituitarism
		Pemphigus
		Periarteritis
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Regional ileitis (Crohn’s disease)
		Reticulum cell sarcoma
		Retroperitoneal fibrosis
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation for those, patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in children under the age of sixteen years
		Sympathetic ophthalmitis
		Systemic lupus erythematosus

First Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
188	Prednisone Tablets, B.P.—continued	Temporal arteritis
		Thrombocytopenic purpura
		Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
		Type II nephritis
		Ulcerative colitis proven by sigmoidoscopy or radiological report
		With the written authority of the Director-General, for the treatment, in conjunction with other therapy—
		(a) of chronic or recurrent asthma in the cats of a patient whose asthma interferes seriously with his normal activities of life; or
		(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn
189	Procarbazine Hydrochloride......	Treatment in neoplastic disease
190	Progesterone................	Progesterone deficiency proven by hormonal assay of lateral wall smear
191	(1) Propranolol Hydrochloride, 40 mg. Tablets	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Propranolol Hydrochloride Injection
192	Propranolol Hydrochloride, 10 mg. Tablets	With the written authority of the Director-General, Hypertrophic subaortic stenosis
193	Prosobee..................	With the written authority of the Director-General—
		Galactosaemia
		Homocystinuria
		Lactose intolerance
		Milk allergy in children under the age of four years
194	Protriptyline Hydrochloride......	Any disease or condition in a pensioner
		Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Protriptyline Hydrochloride
		With the written authority of the Director-General—
		The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
195	Pyrazinamide...............	Any disease or condition in a patient receiving treatment in or at an approved hospital
196	(1) Pyridostigmine Injection, B.P.	Myasthenia gravis
	(2) Pyridostigmine Tablets, B.P.
197	Pyridoxine Hydrochloride Tablets	Homocystinuria
		Peripheral neuritis due to isoniazid therapy
		Radiation sickness
198	Pyrimethamine Tablets.........	Treatment of—
		Toxoplasmosis
		Malaria
199	(1) Quinine Bisulphate Tablets, B.P.	Dystrophia myotonica
	(1) Quinine Bisulphate Tablets, B.P.	Malaria
	(2) Quinine Dihydrochloride Tablets	Myotonia atrophica
	(2) Quinine Dihydrochloride Tablets	Myotonia congenita
	(3) Quinine Hydrochloride Tablets	Any disease or condition in a pensioner
	(4) Quinine Sulphate Tablets, B.P.

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
200	(1) Riboflavine Tablets.........	Any disease or condition in a pensioner
	(2) Senna Fruit Extract (standardized)
201	(1) Sodium Aminosalicylate Tablets, B.P.	Tuberculosis
	(2) Sodium Aminosalicylate Injection
	(3) Sodium Aminosalicylate Cachets
	(4) Sodium Aminosalicylate Granules
	(5) Sodium Aminosalicylate with Isoniazid, B.P.
202	Sodium Folate...............	Macrocytic anaemia
		Sprue or the sprue-like syndrome
203	Soyalac...................	With the written authority of the Director-General—
		Galactosaemia
		Homocystinuria
		Lactose intolerance
		Milk allergy in children under the age of four years
204	Spiramycin.................	Serologically proven active toxoplasmosis
		Staphylococcal septicaemia or staphylococcal pneumonia
		Any gram positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins
205	Spironolactone Tablets, B.P.......	With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate
		Myasthenia gravis
206	Stanolone..................	Mammary carcinoma
		With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteroids
207	Stanozolol.................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteroids
208	(1) Stilboestrol Injection........	Carcinoma of the prostate
	(2) Stilboestrol Tablets, B.P.	Mammary carcinoma
		Any disease or condition in a pensioner
		Hereditary telangiectasis
209	Streptomycin Sulphate Injections	Bacillary dysentery that is resistant to the sulphonamides
		Brucellosis
		Chancroid
		Endocarditis due to Streptococcus faecalis or Streptococcus viridans
		Friedlander bacillus infections
		Haemophilus influenzae infections
		Plague
		Pseudomonas pyocyanea infections
		Rat-bite fever (Streptobacillus moniliformis)
		Salmonella infections
		Surgical conditions of the bowel (pre-operative and post-operative)
		Surgical conditions of the thoracic organs
		Tuberculosis
		Tularaemia
		Urinary tract infections that are resistant to the sulphonamides

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
210	Sulphasalazine...............	Ulcerative colitis
211	Sulphomyxin Sodium..........	Any disease or condition in a patient receiving treatment in or at an approved hospital
212	Sulthiame..................	For use where other anticonvulsants have failed
213	(1) Surgical Cement...........	Ileostomy or colostomy conditions
	(2) Surgical Cement Solvent	For use with surgical appliances
214	(1) Sustanon................	Castration syndrome (male)
	(2) Testosterone Implants, B.P.	Klinefelter Reifenstein Albright syndrome
	(3) Testosterone Enanthate	Mammary carcinoma
	(4) Testosterone Propionate Injection, B.P.
215	Tetanus Antitoxin, B.P. (Bovine)	Patients who have previously received an injection of equine serum
216	Tetanus Immune Globulin (Human)	With the written authority of the Director-General, where patients are known to be sensitive to equine serum and bovine serum
217	Tetracosactrin...............	Any disease or condition in a patient receiving treatment in or at an approved hospital
218	(1) Tetracycline Capsules, B.P.....	Brucellosis
	(2) Tetracycline Tablets, B.P.	Intestinal amoebiasis
	(3) Tetracycline Injections	Leptospirosis
	(4) Rolitetracycline	Lymphogranuloma venereum
	(5) Tetracycline Hydrochloride Granules, Paediatric Drops and Syrup	Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
	(6) Tetracycline with a buffering agent
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
219	(1) Tetracycline with a buffering agent and Amphotericin B	Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis
	(2) Tetracycline with a buffering agent and Nystatin
	(2) Tetracycline with a buffering agent and Nystatin	A second or repeated course of broad spectrum antibiotic therapy for—
	(3) Tetracycline Hydrochloride with Nystatin
	(3) Tetracycline Hydrochloride with Nystatin	Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
220	(1) Thiambutosine Tablets, B.P....	Hansen’s disease
	(2) Thiambutosine Injection
221	Thiamine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner.
222	Thiethylperazine Tablets and Suppositories	Radiation sickness
	Thiethylperazine Tablets and Suppositories	Nausea resulting from cytotoxic therapy
223	(1) Thioridazine Tablets, B.P......	Any disease or condition in a pensioner
	(2) Thioridazine	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
223	(1) Thioridazine Tablets, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
	(2) Thioridazine—continued
		Thioridazine
		Thioridazine Tablets, B.P.
		With the written authority of the Director-General—
		Huntington’s chorea
		Late-stage malignancy
		Radiation sickness
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
224	Thyrotrophin................	Any disease or condition in a patient receiving treatment in or at an approved hospital
225	Tragacanth, Indian (Gum Karaya)	Ileostomy or colostomy conditions
226	Trasylol...................	Any disease or condition in a patient receiving treatment in or at an approved hospital
227	Tretamine..................	Treatment in neoplastic disease
228	Triacetyloleandomycin.........	Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Mycoplasma pneumoniae (Eaton’s Agent)
		Psittacosis
		Rickettsial infections
		Staphylococcal septicaemia or staphylococcal pneumonia
		Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
229	(1) Trifluoperazine Tablets, B.P....	Any disease or condition in a pensioner
	(2) Trifluoperazine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets, B.P.
		With the written authority of the Director-General—
		Huntington’s chorea
		Late-stage malignancy
		Radiation sickness
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
230	Triglyde...................	With the written authority of the Director-General—
		Proven malabsorption
231	Trimetaphan Injection, B.P.......	Hypotensive for anaesthesia
232	Vadrine...................	Any disease or condition in a patient receiving treatment in or at an approved hospital
233	Vasopressin Nasal Spray........	Diabetes insipidus
234	Velactin...................	With the written authority of the Director-General—
		Galactosaemia
		Homocystinuria
		Lactose intolerance
		Milk allergy in children under the age of four years
235	(1) Vinblastine Sulphate........	Treatment in neoplastic disease
	(2) Vincristine Sulphate
236	(1) Viomycin Sulphate.........	Tuberculosis
	(2) Viomycin Sulphate Injection, B.P.
237	Vitamin A with Thiamine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D	Any disease or condition in a pensioner
238	Disodium Cromoglycate........	Any disease or condition in a patient receiving treatment in or at an approved hospital

Printed for the Government of the Commonwealth by W. G. Murray at the

Government Printing Office, Canberra

Administered by Department of Health, Disability and Ageing

Interactions

Legislation content

Interactions

Authorises

All Versions